Global study following adults with PSC
Part of Digestive system clinical trials.
This study follows adults with primary sclerosing cholangitis (PSC) over time to learn more about the condition. It is observational, meaning no new treatments are tested—just regular checkups and data collection to better understand PSC.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of 'large duct' PSC (the common kind).
- You cannot have any other major liver disease (like hepatitis or alcoholic liver disease).
- You cannot have had a liver transplant or have severe liver damage (decompensated cirrhosis).
- You cannot have active liver, bile duct, or colon cancer (though some past cancers are okay).
- You cannot be in another PSC drug trial or have been in one in the last 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects bile and uses it to grow small lab models (organoids) from people with primary sclerosing cholangitis (PSC) and from people without PSC. Researchers want to better understand how PSC changes bile cells, which could improve future diagnosis or treatments.
This study follows people diagnosed with primary sclerosing cholangitis to better understand the condition over time. It may help doctors learn which factors affect health and care, and improve future treatment decisions.
This study creates mini-livers (colangioids) from tiny tissue samples to find genetic reasons for atypical primary sclerosing cholangitis (aPSC), a rare liver disease. It aims to help doctors better understand and diagnose the condition.
This study uses a PET/MRI scan to take detailed pictures of the liver and bile ducts in people with PSC. The goal is to better understand the disease and possibly find new ways to track it.
This trial tests whether fenofibrate can prevent primary sclerosing cholangitis (PSC) from coming back after a liver transplant. It is for adults who had a liver transplant for PSC between 1 and 7 years ago and have certain risk factors.
This trial tests a new treatment called LB-P8 for people with primary sclerosing cholangitis (PSC), a liver disease. It aims to see if LB-P8 is safe and can help slow the disease down. You may join if you meet certain health requirements.
Hear when a new PSC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.